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REGIOSELECTIVE HYDROXYLATION, 
FUNCTIONALISATION AND PROTECTION OF 
SPIROLACTAMS II 
FIELD OF THE INVENTION 
[0001] The present invention relates to neW regioselec 
tively hydroxylated, protected and functionaliZed spirolac 
tams and to processes for their synthesis. 
BACKGROUND OF THE INVENTION 
[0002] Lactams are compounds of high interest due to 
their biological activities, for example Well knoWn [3-lac 
tams such as some penicillins, cephalosporins and carbap 
enems have antibacterial activity. 
[0003] Spirolactams are one particular class of lactams 
that have shoWn interesting biological properties. Some 
spiro-fused aZetidinones have been described as having 
antibacterial activity, see US. Pat. No. 4,680,388, or hypo 
cholesterolemic properties, see for example W0 94 17038. 
Additionally, if these compounds have the adequate func 
tionality they are valuable intermediates toWards different 
families of compounds. The spirolactam ring is the equiva 
lent of an alpha amino or hydroxy aminoacid and opens 
many possibilities in diastero and/or enantioselective syn 
thesis. 
[0004] MiyaZaWa, E. et al. in Helerocycles, vol 59, 1:149 
l60 “Synthesis of spiro-fused nitrogen heterocyclic com 
pounds via N-methoxy-N-acylnitrenium ions using phe 
nyliodine (III) bis(tri?uoroacetate) in tri?uoroethanol” 
describe a process to obtain functionalised spirolactams 
including some spirodienones. 
[0005] KukugaWa, Y. e al. in]. Org. Chem. 2003, vol. 68, 
6739-6744 “Intramolecular cycliZation With nitrenium ions 
generated by treatment of N-acylaminophthalimides With 
hypervalent iodine compounds: formation of lactams and 
spirofused lactams” describes the formation of functiona 
lised spirolactams having diene and dienone funcionalities. 
[0006] The conduritols, aminoconduritols, aminoinositols 
and their derivatives also possess interesting biological 
properties, some of them have been shoWn as being antitu 
moral and antibiotic. Although some synthetic processes 
exist for these compounds (See Yong-Uk KWon et al, J. Org. 
Chem. 2002, v1. 67, 3327-3338 “Facile syntheses of all 
possible diastereomers of conduritol and various derivatives 
of inositol stereoisomers in high enantiopurity from myo 
inositol”), there are still dif?culties to obtain these com 
pounds or corresponding analogues. 
[0007] As it is apparent from the above, any ef?cient 
process for producing functionalised spirolactam com 
pounds in high yield, With various functionalities, intro 
duced in a controlled and regioselective manner, Would be a 
Wellcome contribution to the art and Will open the door to a 
variety of biologically active compounds. 
SUMMARY OF THE INVENTION 
[0008] Starting from the compounds described in our 
applications EP 04380l04.2 and EP04076477.l, We found a 
basic set of processes that alloWs the controlled obtention of 
very stable, highly functionalised, spiro-fused aZetidinones 
Which are useful as intermediate compounds in the prepa 
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ration of a variety of chemical structures, including, if 
necessary, by means of chimio-, loco-, regio-, diastero 
and/or enantioselective processes. Additional carbon struc 
tures can be incorporated at the desired positions by means 
of simple reactions, generating neW intermediates of inter 
est. 
[0009] In one aspect the invention provides a compound of 
formula I: 
formula I 
R5 R6 
R3 R2 
R4 R1 
Z N W 
Y \Y/ 
0 
wherein R1 and R2 are each independently selected from H, 
OH or OPR; 
[0010] R3 and R4 are each independently selected from H, 
OH, OPR, =0, cyano, substituted or unsubstituted alkyl, 
substituted or unsubstituted aryl, substituted or unsubsti 
tuted heterocyclyl, substituted or unsubstituted alkoxy, 
substituted or unsubstituted aryloxy, substituted or unsub 
stituted amino or halogen, 
[0011] R5 and R6 together are =0 or iOi(CHO2)mi, 
Wherein m is selected from 1, 2, 3, 4 or 5; or R5 is selected 
from H, OH, OPR and R6 is selected from hydrogen, 
cyano, substituted or unsubstituted alkyl, substituted or 
unsubstituted cycloalkyl, substituted or unsubstituted alk 
enyl, substituted or unsubstituted alkinyl, substituted or 
unsubstituted aryl, substituted or unsubstituted heterocy 
clyl, 
[0012] With the proviso that at least one of R1, R2, R3, R4 
or R5 is OH or OPR; 
[0013] PR is an hydroxyl protecting group Which can be 
the same or different on each of R1, R2, R3, R4 or R5; 
[0014] the dotted line represents a single or double bond, 
With the proviso that When both R1 and R2 or R3 and R4 
are H then there is a double bond betWeen the tWo C to 
Which the H are linked; 
[0015] Z is i(CRaRb)ni Wherein n is a number selected 
from 1, 2 or 3 and Ra and Rb are each independently 
selected from hydrogen, substituted or unsubstituted 
alkyl, substituted or unsubstituted cycloalkyl, substituted 
or unsubstituted alkenyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heterocyclyl, substituted or 
unsubstituted alkoxy, substituted or unsubstituted aryloxy, 
substituted or unsubstituted amino or halogen; 
[0016] Y is selected from 40*, iSi, iN(RaRb)i or 
iC(O)i, Wherein Ra and Rb are as previously de?ned 
and do not form a cyclic ring; 
[0017] W is a group selected from substituted or unsub 
stituted arylalkyl, substituted or unsubstituted heterocy 
clylalkyl, substituted or unsubstituted alkenyl; or a salt, 
complex or solvate thereof. 
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[0018] In one embodiment We prefer that n is 1. In this 
case Z is preferably 4CHRai.In another embodiment W is 
arylalkyl, preferably benZyl. In a further embodiment Y is 
preferably iOi. 
[0019] The invention also provides for a process for the 
preparation of a compound according of formula I, Which 
comprises in any order one or more of a step selected from 
the group consisting of: 
[0020] a) hydroxylation or dihydroxylation 
[0021] b) hydroxyl or carbonyl protection 
[0022] c) nucleophilic attack at the carbonyl group or 
double bonds 
[0023] d) hydroxyl inversion 
[0024] e) allylic rearrangements applied to a compound of 
formula IV: 
formula IV 
Wherein Z, Y and W are as de?ned above. 
DETAILED DESCRIPTION OF THE 
INVENTION 
[0025] The invention provides compounds of formula I as 
above de?ned. In the compounds of formula I, the group Z 
gives rise to a ring of 4, 5 or 6 members. Substitution on 
position Z creates a stereogenic center that could induce 
selective functionalisation on the benZodienone moiety. In a 
preferred embodiment Z is i(CHRa)ni, the stereogenic 
center alloWs for the selectivity or speci?city of any further 
reaction. Although rings of 5 or 6 are also comprised Within 
the scope of the invention, in one embodiment the [3-lactam 
ring (n=l) is preferred because of the further uses that can 
be given to such compounds. 
[0026] The group Y in the compounds of formula I plays 
a role in the stability and conformation. In an embodiment 
Y is preferably iOi, although other atoms are not 
excluded as long as the ?nal product is stable. 
[0027] The W group is important for the stabiliZation of 
the compound of formula I. Preferably it comprises unsat 
urated bonds or aromatic groups to increase the at interaction 
betWeen W and the double bonds. Aralkyl groups and 
alkenyl groups are preferred since they give the best stabil 
ity. In a particular embodiment, W is iCRaRb-Q or -SiR 
aRb-Q since the stability of the conformation is further 
improved by the presence of a iCRaRbi or a iSiRaRbi 
linker betWeen Y and the substituent Q Which has at (pi) 
interactions With the benZodienone moiety. The linker is 
preferably 4CHRai. This Will advantageously open the 
Way to diastero- and/or enantioselective synthesis in addi 
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tion to the selection for one face Which is explained beloW. 
Depending on the siZe of Ra it can also modulate the at (pi) 
interactions. 
[0028] In one embodiment W is an aralkyl group. Among 
the aryl groups susbtituted or unsubstituted phenyl and 
naphthyl are preferred. Heterocyclylalkyl groups are also 
envisaged. Phenyl is the simplest subtituent and gives good 
results. 
[0029] In the above de?nition of compounds of formula (I) 
and in the description the folloWing terms have the meaning 
indicated: 
[0030] “Alkyl” refers to a straight or branched hydrocar 
bon chain radical consisting of carbon and hydrogen atoms, 
containing no saturation, having 1-12, preferably one to 
eight carbon atoms, and Which is attached to the rest of the 
molecule by a single bond, e. g., methyl, ethyl, n-propyl, 
i-propyl, n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals may 
be optionally substituted by one or more substituents such as 
halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, 
alkoxycarbonyl, amino, nitro, mercapto and alkylthio. 
[0031] “Alkoxy” refers to a radical of the formula iORa 
Where Ra is an alkyl radical as de?ned above, e. g., methoxy, 
ethoxy, propoxy, etc. “Aryloxy” refers to a radical of for 
mula 4ORb Wherein Rb is an aryl radical as de?ned beloW. 
[0032] “Amino” refers to a radical of the formula-NH2, 
iNHRa, iNRaRb. 
[0033] “Aryl” refers to an aromatic hydrocarbon radical 
such as phenyl, naphthyl or anthracyl. The aryl radical may 
be optionally substituted by one or more substituents such as 
hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, 
nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoxycar 
bonyl, as de?ned herein. 
[0034] “Aralkyl” refers to an aryl group linked to an alkyl 
group such as benZyl and phenethyl. 
[0035] “Cycloalkyl” refers to a saturated carbocyclic ring 
having from 3 to 8 carbon atoms. 
[0036] “Heterocyclyl” refers to a stable 3- to l5-mem 
bered ring Which consists of carbon atoms and from one to 
?ve heteroatoms selected from the group consisting of 
nitrogen, oxygen, and sulfur, preferably a 4-to 8-membered 
ring With one or more heteroatoms, more preferably a 5-or 
6-membered ring With one or more heteroatoms. For the 
purposes of this invention, the heterocycle may be a mono 
cyclic, bicyclic or tricyclic ring system, Which may include 
fused ring systems; and the nitrogen, carbon or sulfur atoms 
in the heterocyclyl radical may be optionally oxidised; the 
nitrogen atom may be optionally quaterniZed; and the het 
erocyclyl radical may be partially or fully saturated or 
aromatic. Examples of such heterocycles include, but are not 
limited to, aZepines, benZimidaZole, benZothiaZole, furan, 
isothiaZole, imidaZole, indole, piperidine, piperaZine, 
purine, quinoline, thiadiaZole, tetrahydrofuran. 
[0037] “Hydroxyl protecting group” refers to a group that 
blocks the OH function for further reactions and can be 
removed under controlled conditions. The hydroxyl protect 
ing groups are Well knoWn in the art, representative protect 
ing groups are silyl ethers such as trimethylsilyl ether, 
triethylsilyl ether, tert-butyldimethylsilyl ether, tert-butyl 
diphenylsilyl ether, tri-isopropylsilyl ether, diethylisopro 
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pylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl ether, 
di-tert-butylmethylsilyl ether; alkyl ethers such as methyl 
ether, tert-butyl ether, benZyl ether, p-methoxybenZyl ether 
, 3,4-dimethoxybenZyl ether, trityl ether; allyl ether; 
alkoxymethyl ether such as methoxymethyl ether, 2-meth 
oxyethoxymethyl ether, benZyloxymethyl ether, p-methoxy 
benZyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl 
ether; tetrahydropyranyl and related ethers; methylthiom 
ethyl ether; Esters such as acetate ester, benZoate ester; 
pivalate ester; methoxyacetate ester; chloroacetate ester; 
levulinate ester; Carbonates such as benZyl carbonate, p-ni 
trobenZyl carbonate, tert-butyl carbonate, 2,2,2-trichloroet 
hyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl car 
bonate. Additional examples of hydroxyl protecting groups 
can be found in reference books such as Greene and Wuts’ 
“Protective Groups in Organic Synthesis”, John Wiley & 
Sons, Inc., NeW York, 1999. 
[0038] References herein to substituted groups in the 
compounds of the present invention refer to the speci?ed 
moiety that may be substituted at one or more available 
positions by one or more suitable groups, e. g., halogen such 
as ?uoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; 
aZido; alkanoyl such as a Cl-6 alkanoyl group such as acyl 
and the like; carboxamido; alkyl groups including those 
groups having 1 to about 12 carbon atoms or from 1 to about 
6 carbon atoms and more preferably l-3 carbon atoms; 
alkenyl and alkynyl groups including groups having one or 
more unsaturated linkages and from 2 to about 12 carbon or 
from 2 to about 6 carbon atoms; alkoxy groups having one 
or more oxygen linkages and from 1 to about 12 carbon 
atoms or 1 to about 6 carbon atoms, aryloxy such as 
phenoxy; alkylthio groups including those moieties having 
one or more thioether linkages and from 1 to about 12 
carbon atoms or from 1 to about 6 carbon atoms; alkylsul? 
nyl groups including those moieties having one or more 
sul?nyl linkages and from 1 to about 12 carbon atoms or 
from 1 to about 6 carbon atoms; alkylsulfonyl groups 
including those moieties having one or more sulfonyl link 
ages and from 1 to about 12 carbon atoms or from 1 to about 
6 carbon atoms; aminoalkyl groups such as groups having 
one or more N atoms and from 1 to about 12 carbon atoms 
or from 1 to about 6 carbon atoms; carbocylic aryl having 6 
or more carbons, particularly phenyl or naphthyl and aralkyl 
such as benZyl. Unless otherWise indicated, an optionally 
substituted group may have a substituent at each substitut 
able position of the group, and each substitution is indepen 
dent of the other. 
[0039] In our copending application, EP04380104.2, 
Which is incorporated herein by reference in its entirety, We 
describe neW compounds having a formula IV and processes 
for their obtention: 
formula IV 
Z N W 
Y \Y/ 
0 
wherein Z and Y are as above de?ned and W is a group With 
su?icient electronic density to stabiliZe the compound 
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through at (pi) interactions With the benZodienone moiety, 
preferably a group having unsaturated bonds or aromatic 
groups, more preferably it is selected from substituted or 
unsubstituted arylalkyl, substituted or unsubstituted hetero 
cyclylalkyl, or substituted or unsubstituted alkenyl. 
[0040] These compounds are remarkably stable due to iE 
interactions betWeen the W group and the benZodienone 
moiety. Additionally these compounds adopt a preferential 
conformation in Which the W group blocks one of the faces 
of the benZodienone (hereinafter the P face) and is “?xed” 
there by the ruinteractions, directing further reactions to the 
free face of the benZodienone moeity (hereinafter the a face). 
[0041] Taking advantage of this, We have found that 
starting from these compounds it is possible to regioselec 
tively hydroxylate, functionalise and protect the different 
positions of the benZodienone group, to give a broad range 
of stable compounds having the desired functionality and 
protection at each of the 5 available positions. Further, 
carbonated substituents can be introduced on the obtained 
compounds, to generate a carbon skeleton at Wish. All these 
highly functionalised compounds are useful as building 
blocks for a Wide variety of bioactive compounds. 
[0042] In our copending EP04076477.1 We describe the 
dihydroxylation that takes place regioselectively, only via 
the a face: 
O O 
OH 
—> 
OH 
ZYN\Y/W ZYN\Y/W 
O O 
[0043] This oxidation occurs readily under mild condi 
tions, such as using OsO4 in a polar solvent, for example a 
mixture of Water an ketone, in the presence of an amine such 
as N-methylmorpholine N-oxide. Alternative oxidation sys 
tems Will be readily apparent to the person skilled in the art 
and can be found in standard references for organic synthesis 
such as Noyori, R. “Asymmetric catalysis in organic syn 
thesis”, John Wiley and Sons, Inc. (1994) or Ojima, I. 
“Catalytic asymmetric synthesis VCH, (1993). 
[0044] The dihydroxylated compound can be selectively 
protected. Indeed, When carrying out a protection such as 
With Cl-TBDMS We found that the hydroxyl at position 6 
reacted until being completely protected, and only then the 
OH at position I is protected. 
O O 
OH OPr 
—> 
OH OH 
ZYN\Y/W ZYN\Y/W 
O O 
[0045] Without being bound by theory, We believe that this 
is due to the existence of CiH at interactions betWeen the 
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H at position 6 and the W group. This means that the ‘OH 
at position 6 is in an equatorial conformation, more reactive, 
While the ‘OH at position 5 is in an axial conformation, less 
reactive. This alloWs the selective reaction of one position 
With respect to the other. 
OH (axial) 
[0046] Therefore, both the facial selection (a versus [3) 
When carrying out the hydroxylation, and the different 
reactivity of positions 5 and 6, due to the particular confor 
mations generated by the presence of the W group and its 
interactions With the rest of the molecule, alloWs for a ?ne 
tuned control of the functionalisation of the molecule. 
[0047] The tWo hydroxy groups can be protected With the 
same protecting group as explained above, or With different 
protecting groups, ?rst protecting the position 6 and then the 
position 5: 
O 
OPrl 
OPrZ 
Z N W 
Y \ Y / 
O 
OPrl 
PI‘Z 
OH 
Z N W 
Y \Y/ 
O O 
[0048] To introduce the hydroxyl protecting groups stan 
dard procedures can be used, such as those described in 
Greene and Wuts’ “Protective Groups in Organic Synthe 
sis”, John Wiley & Sons, Inc., NeW York, 1999 or Kocienski, 
P. J. “Protecting Groups”, 3rd Ed. Thieme Chemistry, 2003. 
[0049] In another embodiment the carbonyl group can also 
be selectively functionaliZed for example by Nucleophilic 
addition. Importantly, the lactam group does not react 
instead because it has a Weinreb type of amide. Thus 
cyanides, organolithium compounds, Grignard’s reagents, 
ketones among other can be easily added to introduce the 
desired functionality at this position. If an hydride is used 
then an hydroxy at position 3 is generated. Suitable proce 
dures for this kind of reactions are knoWn in the art and can 
be found for example in Fischer, A. et al J. Org. Chem, 1987, 
52, 4464-4468 “Formation of 4-nitrocyclohexa-2,5-dienols 
by addition of organolithium reagents to 4-alkyl-4-nitrocy 
clohexa-2,5-dione”; Wipfet al., Angew. Chem. Int. Ed. Engl. 
1997, 36, no. 7, 764-767; Fischer, A. et al., Tetrahedron leZL, 
1980, 21, 701-704; Carreno, M. et al., J. Org. Chem, 1997, 
62, 26, 9128-9137. 
[0050] The additions can be done independently of the 
functionalisation of the other positions. We have found that 
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When the compound of formula IV is ?rst dihydroxylated 
and then the addition to the carbonyl is carried out, complete 
stereoselectivity is achieved. 
o 
oPRl 
_> 
oPR2 
ZYN\Y_W 
o 
[0051] Depending on the Nucleophilic reagent used the 
product of the reaction can have different structures. For 
example, if an epoxide With a de?ned conformation is 
desired, then a reagent such as an S ylide can be used. Under 
conditions of a Corey’s epoxidation only one epoxide is 
obtained [a) E. J. Corey; Michael Chaykovsky J. Am. Chem. 
Soc. 87, 1965, 1353-1364. b) Steven P. Tanis, Mark C. 
McMills, Paul M. Herrinton J. Org. Chem. 50, 1985, 5887 
5889. c) Malcolm Chandler, Richard Conroy, Anthony W. J. 
Cooper, R. Brian Lamont, Jan J. Scicinski, James E. Smart, 
Richard Storer, Niall G. Weir, Richard D. Wilson and Paul 
G. Wyatt J. Chem. Soc. Perkin Trans. 1, 1995, 1189-1197]: 
o 
oPRl 
_> 
oPR2 
ZYN\Y/W 
o 
[0052] Alternatively a double bond can be generated, for 
example under Wittig’s conditions. In this case the Nucleo 
phile is a C ylide. 
o 
oPRl OPR1 
_> 
oPR2 OPRZ 
ZYN\Y/W ZYN\Y/W 
o o 
[0053] The double bond can have further substituents at 
position 10 depending on the reagent used. From this 
structure, With tWo differentiated double bonds, further 
reactions can be carried out as We Will explain beloW. 
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[0054] If the Nucleophile is directed to the double bond 
instead of the carbonyl then the functionality or the addi 
tional carbon group is added at position 9: 
O O 
OPRl OPR1 
_> 
oPR2 Nu oPR2 
ZYN\Y/W ZYN\Y/W 
O O 
[0055] In such a Way for example cyanide or an allylic 
group can be introduced at position 9, opening neW possi 
bilities for further construction. It Will be understood that 
once this Nu is introduced, then the above reactions on the 
carbonyl group, such as another nucleophilic attack can be 
done to generate neW structures. For example, if Corey’s 
epoxidation or Wittig’s reaction are carried out on this neW 
substrate, the folloWing structures can be obtained: 
0 
011111 011111 
_> 
Nu oPR2 
ZYN\Y/W O \ 
[0056] The epoxides can be opened to give an hydroxyl 
group at position 10. This can be done With the simultaneous 
introduction of a Nucleophilic group at position 9: 
oPR3 
oPRl 
oPR2 Nu 
Z N W 
Y \Y/ 
O 
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[0057] In this Way We generate a neW double bond 
betWeen positions 7 and 8 Which again opens many possi 
bilities for further functionalisation. For example, a simple 
dihydroxylation Will generate a highly functionalised struc 
ture, With tWo neW and differentiated hydroxy groups: 
oPR3 
oPRl 
Nu oPR2 
[0058] Under mild conditions (for example OsO4 as desci 
bed above) the initial dihydroxy compound can be hdroxy 
lated again to generate a structure With 4 hydroxy groups: 
0 o 
oPRl H00,“ OPR1 
—> . 
oPR2 Ho“““ oPR2 
ZYN\Y/W ZYN\Y/W 
o o 
If desired, the stereochemistry of the free hydroxy groups 
can be subjected to inversions. It Will be readily apparent to 
the person skilled in the art that these rae suitable precursor 
to inositols and conduritols , through opening of the lactame 
ring and removing, latter on, their acetate portion by pro 
cesses that envolve retroaldolic or retro-Staudinger like 
reactions. Other analogues of these valuable biological com 
pounds can be prepared if We start from the different 
structures as We are describing here. 
[0059] The dihydroxylation can be carried out on the 
product of Wittig’s reaction, in this case tWo dilTerentiated 
hydroxy groups are introduced at positions 7 and 10: 
oPRl 
_> 
oPR2 
ZYN\Y_W 
o 
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[0060] If instead of a dihydroxylation We do an epoxida 
tion With, for example, a peroxide under mild conditions, We 
obtain an epoxide With just the opposite con?guration at 7 
When compared With the epoxide obtained directly under 
Corey’s conditions: 
oPRl 
oPR2 
Z N 
Y \Y_W 
O 
[0061] Thus, even through all these reactions We are still 
able to control the stereochemistry at the different positions. 
This alloWs us to prepare intermediates With the adequate 
con?guration in order to reach downstream the different 
stereoisomers of biologically active compounds. 
[0062] The presence of vicinal hydroxyl groups alloWs the 
simultaneous protection of tWo of them through the use of 
diol protecting groups if desired. Among the diol protecting 
groups that can be used We have 0,0-acetals such as 
isopropylidene acetals (acetonides); cyclohexylidene and 
cyclopentylidene acetals; arylmethylene acetals; methylene 
acetals; diphenylmethylene acetals; 1,2-diacetals such as 
dispiroketal (dispoke) derivatives, cyclohexane-l,2-diac 
etals, butane-2,3-diacetals; silylene derivatives; l,l,3,3-tet 
raisopropyldisiloxanylidene derivatives or N,O-acetals. 
Additional examples of diol protecting groups can be found 
in reference books such as Greene and Wuts’ “Protective 
Groups in Organic Synthesis”, John Wiley & Sons, Inc., 
NeW York, 1999. Additionally, borolanes can be formed on 
the tWo vicinal hydroxy groups, for example using phenyl 
bor‘ic acid. 
[0063] For example, dihydroxylation and protection can 
be carried out simultaneously: 
oPRl 
Or, if desired, only one of the hydroxy groups can be 
selectively protected due to their different nature (primary 
versus tertiary alcohol): 
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[0064] A carbolactone can be produced through reaction 
of a functionalised Nucleophile at the carbonyl group and 
lactoniZation With the unprotected hydroxyl group Which is 
present at position 8, for example using methyl (triph 
enylphosphoranylidene)acetate: 
0 
H00,’ oPRl 
—> 
no“ oPR2 
z N W 
Y \Y/ 
o 
Again, We obtain a neW structure plenty of functionalities 
With can be further subjected to additional reactions. 
[0066] As can be understood from the above and Will be 
apparent to the person skilled in the art, due to the particular 
conformation and reactivity characteristics of the described 
compounds, a great number of possibilities can be achieved. 
It is important to point out that the obtained compounds of 
formula I Will present a carefully crafted functionality at the 
different positions 5, 6, 7, 8, 9 and 10, and the desired 
stereochemistry. The same structure can be reached through 
different combinations of the basic reactions. The introduc 
tion of different protecting groups opens the route to very 
selective further reactions by chosing the appropriate pro 
tection-deprotection strategies. 
US 2006/0148778 A1 
[0067] The process to obtain any of these compounds can 
be readily designed by starting from a compound of formula 
IV above and then applying a basic set of reactions selected 
from: 
[0068] a) Hydroxilation or dihydroxylation: as above 
explained, using mild (such as OsO4/ N oxide amine) or 
strong systems (such as RuCl3) depending on the position 
to be hydroxylated. Alternative systems are also envis 
aged. 
[0069] b) Nucleophilic attack at the carbonyl group: for 
example With a carbanion on a sp, sp2 or sp3 C, the 
carbanion can be prepared or generated in situ; or With an 
hydride. The Nucleophilic attack alloWs the introduction 
of neW functionalities, neW carbonated structures and also 
epoxides or double bonds, depending on the reagents 
used. 
oPRl 
Nu oPR2 
Jul. 6, 2006 
[0070] c) Hydroxyl inversion: for example through 
epimeriZation or inversion, for example in Mitsunobu 
conditions. 
[0071] d) Hydroxyl or carbonyl protection: as explained 
above, using the same or different protecting groups in 
conditions as explained above. 
[0072] e) Allylic rearrangements: alloWs migration of a 
double bond. 
[0073] Although each of these procedures is Well knoWn 
and the appropriate reagents can be selected by the person 
skilled in the art of organic synthesis, for example from 
those given in the references above, their application to the 
our structures gives unexpected results in terms of reactivity 
and selectivity. 
[0074] The folloWing scheme I illustrates some of these 
possibilities: 
silll?m?l 
o 
oPRl OPR1 
oPR2 Nu oPR2 
ZYN\Y/W 
o 
/ 
oPRl 
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-continued 
[0075] All the compounds Will be obtained as racemic 
mixtures. However, if enantiopurity is desired, this can be 
achieved by introducing a chiral center in the W group as 
explained above, or using chiral reagents or catalysts. There 
fore the compounds of the present invention represented by 
the above described formula (I) may include pure enanti 
omers depending on the presence of stereogenic centers or 
diastereoisomers. The single isomers, enantiomers or dias 
tereoisomers and mixtures thereof fall Within the scope of 
the present invention. Mixtures of different diasteroisomers 
can be separated by conventional techniques. 
[0076] Unless otherWise stated, the compounds of the 
invention are also meant to include compounds which differ 
only in the presence of one or more isotopically enriched 
atoms. For example, compounds having the present struc 
tures except for the replacement of a hydrogen by a deute 
rium or tritium, or the replacement of a carbon by a 13C- or 
l4C-enriched carbon or l5N-enriched nitrogen are Within the 
scope of this invention. 
[0077] The compounds of the invention may be in crys 
talline form either as free compounds or as solvates (e.g. 
hydrates) and it is intended that both forms are Within the 
scope of the present invention. Methods of solvation are 
generally knoWn Within the art. 
[0078] The invention Will be further illustrated by means 
of examples, Which should not be interpreted as limiting the 
scope of the claims. 
EXAMPLES 
General Methods and Materials. 
[0079] All reactions described beloW Were carried out 
under argon atmosphere unless otherWise noted. The sol 
vents used Were distilled and dried under argon atmosphere 
before use. All starting materials Were purchased commer 
cially (Aldrich, Fluka and Merck) and used Without further 
puri?cation. Flash Chromatography Was executed on col 
umns loaded With 230-400 mesh silica gel Merck. TLC Was 
carried out on silica gel Merck (Kieselgel 60F-254). 
[0080] Melting points (mp) Were determined on a Reichert 
Microscopic Hot-Stage and are uncorrected. 1H and 13C 
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NMR spectra Were measured on a Varian Gemini-200 and a 
Varian lnova-300 spectrometer With (CH3)4Si as an internal 
reference and CDCl3 as solvent unless otherWise noted. Both 
1H and 13C NMR spectral data are reported in parts per 
million (6) relative to residual sign of the solvent (CDCl3, 
7.26 ppm and 77.0 ppm for 1H and 13 C NMR, respectively). 
1H and 13C NMR designations are: s (singlete); br. s (broad 
singlete); d (doublete); br. d (broad doublete); t (triplete); q 
(quartete); m (multiplete). Infrared (IR) spectra Were record 
on a Perkin-Elmer FT-IR spectrometer. UV spectra Were 
record on a Perkin-Elmer 402 spectrometer. LoW-resolution 
mass (LRMS) spectra Were obtained on a HeWlett Packard 
5973 MSD spectrometer With a direct inlet system (El) at 70 
eV. Microanalytical data (E.A.) Were obtained on a Perkin 
Elmer 240C and Heraus CHN4O instruments at the Instru 
mental Analysis Department of Instituto de Quimica 
Organica General (C.S.I.C.). 
[0081] The compounds of general formula I and II Were 
nominated as derivatives of l-aZaspiro[3.5]nonan-2-one and 
Were numerated as described beloW. 
Formula 1 
Formula II 
US 2006/0148778 A1 
Example 1 
[0082] Preparation of rac-4R,5S,6S,7S)-1-benZyloxytert 
butyldimethylsilyloxy-7,1 epoxy-7 —methyl-5 -trimethyl sily 
loxy-1-aZaspirop[3.5]nona-en-2-one (2) 
Me3Sl, n-BuLi 
THF, 00 C. to r.t. 
[0083] To a stirred suspension of powdered trimethylsul 
fonium iodide (52 mg, 0.252 mmol) in THF (0.9 ml) Was 
added dropWise at 0° C. n-butyl lithium (0.16 ml, 1.6 M 
solution in hexane, 0.252 mmol). After stirring of the 
mixture for 15 min at this temperature, only a slight pre 
cipitate remained; a solution of rac-(4R,5S,6S)-1-benZy 
loxy-6-tert-butyldimethylsilyloxy-5-trimethylsilyloxy-1 - 
aZaspiro[3.5]nona-8-en-2,7-dione (1) (100 mg, 0.210 mmol) 
in THF (0.6 ml) Was added dropWise. The mixture Was 
stirred for 30 min at 00 C., and then for 2 h at room 
temperature. The reaction Was quenched With Na2HPO4 0.1 
M bulTer (2.5 ml) and AcOEt (2.5 ml). The layers Were 
separated and aqueous phase Was extracted With AcOEt (3><5 
ml). The combined extracts Were dried over Na2SO4, ?ltered 
and concentrated under reduced pressure. The residue Was 
puri?ed by silica gel column chromatography (hexane 
AcOEt, 8:1) to give rac-(4R,5S,6S,7S)-1-benZyloxytert-bu 
tyldimethylsilyloxy-7,10-epoxy-7-methyl-5 -trimethylsily 
loxy-1-aZaspiro[3.5]nona-8-en-2-one (2) as a loW melting 
point White solid (84 mg, 82%). 
[0084] Rf=0.50 (TLC, hexane-AcOEt, 3:1); yield, 82%; 
White solid; lH-NMR (300MHZ, CDCl3): 6 7.34 (5H, m, 
Ph), 5.52 (1H, d, J=10.1 HZ, H-9), 5.06 (1H, dd, J=10.1, 1.9 
HZ, H-8), 5.00 (1H, partA syst. AB, J=11.5 HZ, OCHzPh), 
4.84 (1H, partBsyst. AB, J=11.5 HZ, OCHzPh), 4.17 (1H, d, 
J=1.9 HZ, H-6), 3.50 (1H, t, J=1.9 HZ, H-5), 3.43 (lH,partA 
syst. AB, J=13.9 HZ, H-3), 2.87 (1H, partA syst. AB, J=5.0 
HZ, H-10), 2.73 (1H, part B syst. AB, J=5.0 HZ, H-10), 2.34 
(1H, part B syst. AB, J=13.9 HZ, H-3), 0.83 (9H, s, 
C(CH3)3), 0.14 (9H, s, Si(CH3)3), 0.04 (3H, s, SiCH3), 0.02 
(3H, s, SiCH3); l3C-NMR (75 MHZ, CDCl3): 6 165.9, 135.7, 
133.1, 129.6, 128.9, 128.6, 128.4, 78.7, 77.4, 68.7, 66.3, 
58.9, 53.0, 40.7, 25.7, 18.2, 0.2, —4.9, —5.0; IR (NaCl, CCl4): 
v 3028, 2956, 2857, 1778, 1472, 1410, 1253, 1152, 1116, 
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987, 930, 879, 839, 778 cm'l; LRMS(API-ES+): III/Z 1001 
(2M+Na)+, 512(M+Na)+, 490(M+H)+. 
Example 2 
[0085] Preparation of rac-(4R,5S,6S)-1-benZyloxy-6-tert 
butyldimethylsilyloxy-7 -methylen-5 
aZaspiro[3.5]nonaen-2-one (3) 
trimethylsilyloxy-1 - 
Me(Ph)3PBr, n-BuLi 
THF, -78° C. to r.t. 
[0086] To a stirred suspension of methyltriphenylphos 
phonium (292 mg, 0.802 mmol) in THF (7.5 ml) Was added 
dropWise at -780 C. n-butyl lithium (0.5 ml, 1.6 M solution 
in hexane, 0.802 mmol) and the resulting light yelloW 
solution Was stirred for 15 min at this temperature. Then, a 
solution of rac-(4R,5S,6S)-1-benZyloxy-6-tert-butyldimeth 
ylsilyloxy-5 -trimethylsilyloxy-1-aZaspiro[3.5]nona-8-en-2, 
7-dione (1) (381 mg, 0.802 mmol) in THF (7.5 ml) Was 
added dropWise and the mixture Was stirred for 1 h at room 
temperature. The reaction Was quenched at 00 C. With H20 
(5 ml), the layers Were separated and aqueous phase Was 
extracted With AcOEt (3><10 ml). The combined extracts 
Were dried over MgSO4, ?ltered and concentrated under 
reduced pressure. The residue Was puri?ed by silica gel 
column chromatography (hexane-AcOEt, 8:1) to give rac 
(4R,5 S,6S)-1-benZyloxy-6-tert-butyldimethylsilyloxy-7 
methylen- 5 -trimethylsilyloxy-1 aZaspiro[3 . 5 ]nona-8 -en-2 - 
one (3) as a colourless oil (257 mg, 68%). Rf=0.58 (TLC, 
hexane-AcOEt, 3:1); yield, 68%; colourless oil; 1H-NMR 
(300 MHZ, CDCl3): 6 7.34 (5H, m, Ph), 5.97 (1H, part A 
syst. AB, J=13.8 HZ, H-9), 5.38 (1H, part B syst. AB, J=13.8 
HZ, H-8), 5.01 (2H, br. s, CH2=C), 4.98 (1H, part A syst. 
AB, J=11.7 HZ, OCHzPh), 4.87 (1H, part B syst. AB, J=11.7 
HZ, OCHzPh), 4.28 (1H, br. s, H-6), 4.06 (1H, br. s, H-5), 
3.47 (1H, partA syst. AB, J=14.1 HZ, H-3), 2.28 (1H, part 
Bsyst. AB, J=14.1, H-3), 0.80 (9H, s, C(CH3)3), 0.15 (9H, s, 
Si(CH3)3), 0.07 (3H, s, SiCH3), —0.01 (3H, s, SiCH3); 
l3C-NMR (75 MHZ, CDCl3): 6 166.0, 144.3, 135.6, 130.6, 
129.3,128.8, 128.6, 128.4, 115.6, 78.6, 76.1, 69.2, 66.6, 
40.3, 25.6, 18.0, 0.3, —4.6, —4.7; IR (NaCl, CC4): v 3028, 
2956, 2927, 2855, 1779, 1656, 1611, 1472, 1367, 1252, 
US 2006/0148778 A1 
1138, 1101, 988, 883, 840 cm'l; LRMS(API-ES+): III/Z 
969(2M+Na)+, 496(M+Na)+, 474(M+H)+. 
Example 3 
[0087] Preparation of rac-(4R,5S,6S,7R)-1-benZyloxy 
tert-butyldimethylsilyloxy-7 —hydroxy-7—hydroxymethyl-5 - 
trimethylsilyloxy-1-aZaspiro[3.5]nona-8en-2-one (4) 
0504, NMO 
—> 
acetone — H2O 
[5:1], r.t 
[0088] To a solution of rac-(4R,5S,6S)-1-benZyloxy-6 
tert-butyldimethylsilyloxy-7-methylen-5-trimethylsily 
loxy-l aspiro[3.5]nona-8-en-2-one (3) (235 mg, 0.496 
mmol) in acetone (4 ml) Was added sequentially at room 
temperature H2O (0.8 ml), N-methylmorpholine N-oxide 
(132 mg, 1.091 mmol) and osmium tetroxide (0.37 ml, 2.5 
Wt. % solution in 2-methyl-2-propanol, 0.030 mmol). The 
resulting mixture Was stirred at room temperature until the 
reaction Was complete (16 h, TLC monitoring, hexane 
AcOEt, 3:1), and then quenched With 10% aqueous Na2S203 
solution (1.5 ml). After 15 min, the mixture Was extracted 
With AcOEt (3><4 ml). The combined organic extracts Were 
dried over Na2SO4, ?ltered and concentrated under reduced 
pressure to give rac-(4R,5S,6S,7R)-1-benZyloxy-6-tert-bu 
tyldimethylsilyloxy-7-hydroxy-7—hydroxymethyl-5-trimeth 
ylsilyloxy-1-aZaspiro[3.5]nona-8-en-2-one (4) as a loW 
melting point pale yelloW solid (240 mg, 95%). Ri=0.13 
(TLC, hexane-AcOEt, 3:1), 0.64 (TLC, hexane-AcOEt, 
1:1); yield, 95%; pale yelloW solid; 1H-NMR (300 MHZ, 
CDCl3): 6 7.41-7.32 (5H, m, Ph), 5.47 (1H, d, J=9.9 HZ, 
H-9), 5.41 (1H, d, J=9.9 HZ, H-8), 5.01 (1H, partAsyst. AB, 
J=11.5 HZ, OCHzPh), 4.84 (1H, part B syst. AB, J=11.5 HZ, 
OCHlPh), 4.48 (1H, br. s, H-6 or H-5), 3.83 (1H, br. s, H-5 
or H-6), 3.67 (1H, br. d, J=11.1 HZ, CH-OH), 3.45 (1H, d, 
J=11.1 HZ, CHi)A)H), 3.24 (1H, br. d, J=12.4 HZ, H-3), 
2.26 (1H, br. d, J=12.4 HZ, H-3), 2.04 (2H, s br., OH), 0.81 
(9H, s, C(CH3)3), 0.19 (9H, s, Si(CH3)3), 0.13 (3H, s, 
SiCH3), 0.08 (3H, s, SiCH3); l3C-NMR (75 MHZ, CDCl3): 
6 165.3, 133.4, 129.5, 129.2, 128.8, 128.6, 128.5, 78.8, 76.2, 
73.7, 68.0, 66.5, 65.8, 40.2, 26.0, 18.1, 0.4, —2.8, —5.4; IR 
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(NaCl, cc14); v 3434, 3028, 2956, 2858, 1755, 1478, 1462, 
1456, 1411, 1389, 1362, 1253, 1141, 1090,918,882, 837, 
756 cm'l; LRMS(API-ES+): III/Z 1037(2M+Na)+, 530(M+ 
Na)", 508(M+H)+. 
Example 4 
[0089] Preparation of rac-(4R,5S,6S,9R)1—benzyloxy-tert 
butyldimethylsilyloxy-9cyano—5-trimethylsilyloxy- 1 -aZa 
spiro[3 .5 ]nonaen-2,7-dione (5) 
[0090] To a stirred solution of cyanotrimethyl silane (56 
pl, 0.411 mmol) and trimethylaluminium (0.19 ml, 2.0 M 
solution in toluene, 0.374 mmol) in THF (0.5 ml) Was added 
at room temperature a solution of rac-(4R,5S,6S)-1-benZy 
loxy-6-tert-butyldimethylsilyloxy-5 -trimethylsilyloxy- 1 - 
aZaspiro[3.5]nona-8-en-2,7-dione (1) (89 mg, 0.187 mmol) 
in THF (0.5 ml). The resulting mixture Was stirred at re?ux 
for 24 h and then concentrated under reduced pressure. The 
residue Was dissolved in toluene (2 ml), Was Washed With 
cold NH4CI sat. (1 ml) and NaZHPO4 0.1 M bulTer (1 ml), 
dried over Na2SO4, ?ltered and concentrated under reduced 
pressure. The residue Was puri?ed by silica gel column 
chromatography (hexane-AcOEt, 5:1) to give rac-(4R,5S, 
6S, 9R)-1 -benZyloxy-6-tert-butyidimethylsilyloxy-9—cyano 
5-trimethylsilyloxy-1-aZaspiro[3.5]nona-8-en-2,7-dione (5) 
as a loW melting point White solid (21 mg, 22%). Rf=0.41 
(TLC, hexane-AcOEt, 3:1); yield, 22%; White solid; 
1H-NMR (300 MHZ, CDCl3): 6 7.44-7.30 (5H, m, Ph), 5.31 
(1H, part A syst. AB, J=10.7 HZ, OCH,)Ph), 5.11 (1H, part 
Bsyst. AB, J=10.7 HZ, OCHzPh), 4.71 (1H, d, J=2.2 HZ, 
H-6), 4.13 (1H, d, J=2.2 HZ, H-5), 3.66 (1H, dd, J=13.4, 5.4 
HZ, H-9), 2.92 (1H, part A syst. AB, J=14.5 HZ, H-3), 2.76 
(1H, part B syst. AB, J=14.5 HZ, H-3), 2.63 (1H, dd, J=13.4, 
5.4 HZ, H-8), 2.21 (1H, t, J=13.4 HZ, H-8), 0.85 (9H, s, 
C(CH3)3), 0.09 (9H, s, Si(CH3)3), 0.08 (3H, s, SiCH3), 
—0.06 (3H, s, SiCH3); l3C-NMR (75 MHZ, CDCl3): 6 201.0, 
164.1, 133.9, 129.5, 129.4, 128.9, 117.1, 80.8, 78.9, 78.0, 
67.3, 42.2, 38.3, 32.0, 25.8, 18.5, 0.5, —4.8, —5.6; IR (KBr): 
US 2006/0148778 A1 
v 3425, 2956, 2927, 2855, 2233, 1772, 1631, 1454, 1364, 
1255, 1107, 1064, 841 cm_l; LRMS(API-ES+): III/Z 525(M+ 
Na)", 503(M+H)+. 
Example 5 
[0091] Preparation of rac-(4R,5S,6S,8S,9S)-1—benzyloxy 
tert-butyldimethylsilyloxy-8, 9-dihydroxy-5trimethylsily 
loxy-1-azaspiro[3.5]nonan-2,7-dione (6) 
Method A. 
TMSO/h 
Ph3P= CHCOOCH3 
—>
“w benzene, r.t 
HO 
O— N 
Ph J 
OTBDMS 
[0092] To a solution of rac-(4R,5S,6S,7S,8S,9S)-1—benzy 
loxy-6-tert-butyldimethylsilyloxy-7-cyano-7,9-dihydroxy 
5,8-bis(trimethylsilyloxy)-1-azaspiro[3.5]nonan-2-one (7) 
(58 mg, 0.095 mmol) in benzene (1.0 ml) Was added at room 
temperature a solution of methyl (triphenylpho sphoranylide 
ne)acetate (76 mg, 0.228 mmol) in benzene (2 ml). The 
mixture Was stirred to re?ux for 11 h. The reaction Was 
quenched With NaZHPO4 0.1M bulTer (3 ml) and AcOEt (3 
ml). The layers Were separated and aqueous phase Was 
extracted With AcOEt (3><6 ml). The combined extracts Were 
dried over Na2SO4, ?ltered and concentrated under reduced 
pressure. The residue Was puri?ed by silica gel column 
chromatography (hexane-AcOEt, 4:1) to give rac-(4R,5S, 
6S,8S,9S)-1—benzyloxy-6-tert-butyldimethylsilyloxy-8,9 
dihydroxy-5 -trimethylsilyloxy- 1 -azaaspiro[3 . 5]nonan-2,7 
dione (6) as a White solid (19 mg, 38 %) and rac-(4R,5S, 
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6S, 8S, 9S)-1 —benzyloxy-6-tert—butyldimethylsilyloxy-9 
hydroxy-7 -methylen-5 -trimethylsilyloxy-1 -azaspiro[3 . 5] 
nonan-2-on-10,8-carbolactone (9) as a White solid (10 mg, 
20%). 
Method B. 
OsO4, NMO 
—> 
acetone— H2O 
O_ [5:1], r.t 
Ph J 
[0093] To a solution of rac-(4R,5S,6S)-1—benzyloxy-6 
tert—butyldimethylsilyloxy-5 -trimethylsilyloxy-1-azaspiro 
[3.5]nona-8-en-2,7-dione (1) (49 mg, 0.103 mmol) in 
acetone (0.5 ml) Was added sequentially at room temperature 
H2O (0.1 ml), N-methylmorpholine N-oxide (26 mg, 0.227 
mmol) and osmium tetroxide (0.077 ml, 2.5 Wt. % solution 
in 2-methyl-2-propanol, 0.006 mmol). The resulting mixture 
Was stirred at room temperature until the reaction Was 
complete (15 h, TLC monitoring, hexane-AcOEt, 1:1), and 
then quenched With 10% aqueous Na2S2O3 solution (0.2 
ml). After 20 min, the mixture Was extracted With AcOEt 
(5><2 ml). The combined organic extracts Were dried over 
Na2SO4, ?ltered and concentrated under reduced pressure. 
The residue Was puri?ed by silica gel column chromatog 
raphy (hexane-AcOEt, 2:1) to give rac-(4R,5S,6S,8S,9S)-1 
benzyloxy-6-tert-butyldimethylsilyloxy-8,9-dihydroxy-5 
trimethylsilyloxy-l-azaspiro[3.5]nonan-2,7-dione (6) as a 
White solid (32 mg, 62%). 
[0094] Rf=0.10 (TLC, hexane-AcOEt, 3:1), 0.55 (TLC, 
hexane-AcOEt, 1:1); yield, 62%; White solid; 1H-NMR (300 
MHz, CDCl3): 6 7.43-7.39 (2H, m, Ph), 7.34-7.32 (3H, m, 
Ph), 5.11 (1H, partA syst. AB, J=10.1 Hz, OCH,2Ph), 5.05 
(1H, part B syst. AB, J=10.1 Hz, OCHzPh), 4.74 (1H, dd, 
J=3.6, 3.4 Hz, H-8), 4.44 (1H, part A syst. AB, J=3.2 Hz, 
H-6), 4.26 (1H, part Bsyst. AB, J=3.2 Hz, H-5), 4.17 (1H, 
dd, J=3.6, 1.6 Hz, H-9), 3.52 (1H, d, J=3.4 Hz, HO-C(8)), 
3.46 (1H, part A syst. AB, J=13.7 Hz, H-3), 2.74 (1H, s, 
HO%(9)), 2.38 (1H, part B syst. AB, J=13.7 Hz, H-3), 
0.85 (9H, s, C(CH3)3), 0.12 (3H, s, SiCH3), 0.08 (9H, s, 
Si(CH3)3), 0.00 (3H, s, SiCH3); l3C-NMR (75 MHz, 
CDCl3): 6 205.7, 165.3, 135.2, 129.3, 129.0, 128.6, 128.3, 
78.7, 77.8, 75.4, 72.1, 67.6, 66.9, 37.5, 25.5, 18.0, 0.3, —5.0, 
—5.2; IR (NaCl, CCl4): v 3435, 2955, 2891, 2858, 1761, 
US 2006/0148778 A1 
1740, 1471, 1253, 1154, 1139, 1109, 887, 884, 780 cm'l; 
LRMS(API-ES+): III/Z 1041(2M+Na)+, 532(M+Na)+, 
510(M+H)+. 
Example 6 
[0095] Preparation of rac-(4R,5 S, 6S,7R)--benZyloxy-tert 
butyldimethylsilyloxy-7,10epoxy-7-methyl-5 -trimethylsily 
loxy-1-aZaspiro[3.5]nonaen-2-one (8) 
CHZCIZ, 
00 C. to r.t 
[0096] To a stirred solution of rac-(4R,5S,6S)-1-benZy 
loxy-6-tert-butyldimethylsilyloxy-7-methylen-5-trimethyl 
silyloxy-1-aZaspiro[3.5]nona-8-en-2-one (3) (200 mg, 0.422 
mmol) in CH2Cl2 (6 ml) Was added at 0° C. 3-chloroper 
oxybenZoic acid (109 mg, 0.633 mmol). The mixture Was 
stirred for 30 min at this temperature and then for 7h at room 
temperature. 
[0097] This mixture Was diluted in CH2Cl2 (3 ml), and 
Washed With NaHCO3 sat. (3><3 ml) and NaCl sat. (1><3 ml). 
The organic phase Was dried over Na2SO4, ?ltered and 
concentrated under reduced pressure. The residue Was puri 
?ed by silica gel column chromatography (hexane-AcOEt, 
8:1) to give rac-(4R,5S,6S,7R)-1-benZyloxy-6-tert-bu 
tyldimethylsilyloxy-7,10-epoxy-7-methyl-5 -trimethylsily 
loxy-1-aZaspiro[3.5]nona-8-en-2-one (8) as a colourless oil 
(170 mg, 82%). 
[0098] Rf=0.50 (TLC, hexane-AcOEt, 3:1); yield, 82%; 
colourless oil; 1H-NMR (200 MHZ, CO(CD3)2): 6 7.44-7.35 
(5H, m, Ph), 5.02 (1H, partAsyst. AB, J=11.1 HZ, OCHlPh), 
4.93 (1H, part B syst. AB, J=11.1 HZ, OCHjPh), 4.34 (1H, 
br. s, H-5 or H-6), 3.58 (1H, br. s, H-6 or H-5), 3.17 (1H, m, 
H-3), 2.87 (2H, s, H-10), 2.44 (1H, d, J=14.1 HZ, H-3), 0.87 
(9H, s, C(CH3)3), 0.16 (9H, s, Si(CH3)3), 0.02 (3H, s, 
SiCH3), 0.01 (3H, s, SiCH3); 1R (NaCl, CCl4): v 3028, 2957, 
2891, 2854, 1781, 1494, 1472, 1407, 1362, 1255, 1151, 
1100, 1055, 994, 881, 842, 803, 778, 753, 666 cm“; 
LRMS(APl-ES+): m/Z 1003(2M+Na)+, 513(M+Na)+, 
490(M+H)+. 
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Example 7 
[0099] Preparation of rac-(4R, 5S, 6S,8S,9S)- 1 -benZyloxy 
tert -butyldimethylsilyloxy-9 -hydroxy-7-methylen- 5 -trim 
ethylsilyloxy-1-aZaspiro[3.5]nonan-2-on-10,8-carbolactone 
(9) 
Method A. 
TMsohh 
" Ph3P=CHCOOCH3 
benzene, r.t 
Ho““ 
O—N 
PhJ 
OTBDMS 
+ 
OTMS 
PhJ 
[0100] To a solution of rac-(4R,5S,6S, 7S, 8S,9S)- l-ben 
Zyloxy-6-tert-butyidimethylsilyloxy-7-cyano-7,9-dihy 
droxy-5,8-bis(trimethylsilyloxy)-1-aZaspiro[3.5]nonan-2 
one (7) (58 mg, 0.095 mmol) in benzene (1.0 ml) Was added 
at room temperature a solution of methyl (triphenylphos 
phoranylidene)acetate (76 mg, 0.228 mmol) in benZene (2 
ml). The mixture Was stirred to re?ux for 11 h. The reaction 
Was quenched With Na2HPO4 0. IM bulTer (3 ml) and AcOEt 
(3 ml). The layers Were separated and aqueous phase Was 
extracted With AcOEt (3><6 ml). The combined extracts Were 
dried over Na2SO4, ?ltered and concentrated under reduced 
pressure. The residue Was puri?ed by silica gel column 
chromatography (hexane-AcOEt, 4:1) to give rac-(4R,5S, 
6S, 8S, 9S)-1 -benZyloxy-6-tert-butyldimethylsilyloxy-8,9 
dihydroxy-5 -trimethylsilyloxy-1-aZaspiro[3.5]nonan-2,7 
dione (6) as a White solid (19 mg, 38%) and rac-(4R,5S,6S, 
8S,9S)-1-benZyloxy-6-tert-butyldimethylsilyloxy-9 
hydroxy-7 -methylen-5 -trimethylsilyloxy-1 -aZaspiro[3 . 5] 
nonan-2-on-10,8-carbolactone (9) as a White solid (10 mg, 
20%). 
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Method B. 
benzene, re?ux 
[0101] To a solution of rac-(4R,5S,6S,8S,9S)-1—benzy 
loxy-6-tert-butyldimethylsilyloxy-8,9-dihydroxy-5-trimeth 
ylsilyloxy-1-azaspiro[3.5]nonan-2,7-dione (6) (59 mg, 
0.116 mmol) in benzene (1 ml) Was added at room tempera 
ture a solution of methyl (triphenylphosphoranylidene)ac 
etate (124 mg, 0.370 mmol) in benzene (3 ml). The mixture 
Was stirred to re?ux for 15h. The reaction Was quenched 
With Na2HPO4 0.1M buffer (3 ml) and AcOEt (3 ml). The 
layers Were separated and aqueous phase Was extracted With 
AcOEt (3><6 ml). The combined extracts Were dried over 
Na2SO4, ?ltered and concentrated under reduced pressure. 
The residue Was puri?ed by silica gel column chromatog 
raphy (hexane-AcOEt, 3:1) to give rac-(4R,5S,6S,8S,9S)-1 
benzyloxy-6-tert-butyldimethylsilyloxy-9-hydroxy-7-meth 
ylen-5 -trimethylsilyloxy-1-azaspiro[3.5]nonan-2-on-10,8 
carbolactone (9) as a White solid (44 mg, 71%). 
[0102] Rf=0.14 (TLC, hexane-AcOEt, 3:1), 0.66 (TLC, 
hexane-AcOEt, 1:1); yield, 71%; White solid; 1H-NMR (300 
MHz, CDCl3): 6 7.42-7.38 (2H, m, Ph), 7.36-7.33 (3H, m, 
Ph), 6.00 (1H, d, J=1.5 Hz, H-10), 5.09 (1H, dd, J=3.6, 1.5 
Hz, H-8), 5.08 (1H, part A syst. AB, J=10.2 Hz, OCH2Ph), 
5.03 (1H, part B syst AB, J=10.2 Hz, OCH2Ph), 4.77 (1H, 
d, J=3.2 Hz, H-5), 4.32-4.27 (2H, m, H-9 and H-6), 3.46 
(1H, partA syst. AB, J=13.8 Hz, H-3), 2.37 (1H, d, J=2.9 Hz, 
HO-C(9)), 2.32 (1H, part Bsyst. AB, J=13.8 Hz, H-3), 0.85 
(9H, s, C(CH3)3), 0.10 (3H, s, SiCH3), 0.09 (9H, s, 
Si(CH3)3), 0.01 (3H, s, SiCH3); l3C-NMR (75 MHz, 
CDCl3): 6 165.4, 165.1, 135.2, 129.4, 128.8, 128.4, 115.8, 
78.8, 78.6, 72.7, 69.5, 67.1, 66.9, 37.6, 25.5, 18.0, 0.4, —4.9; 
IR (KBr): v 3435, 2949, 2927, 2855, 1779, 1747, 1631, 
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1248, 1129, 1101, 840, 616 cm'l; LRMS(API-ES+): III/Z 
1088(2M+Na)+, 556(M+Na)+, 533(M+H)+. 
Example 8 
[01 03] Preparation of rac-(4R,5 S, 6S)-1 —benzyloxy-6-tert 
butyldimethylsilyloxy-7 -methylen- 5 -trimethylsilyloxy-1 - 
azaspiro[3.5]nonaen-2-on-10,8carbolactone (10) 
Ph3P —— CHCOOCH3 
—>
toluene, re?ux 
[0104] To a solution of rac-(4R,5S,6S,8S,9S)-1—benzy 
loxy-6-tert-butyldimethylsilyloxy-8,9-dihydroxy-5-trimeth 
ylsilyloxy-1-azaspiro[3.5]nonan-2,7-dione (6) (19 mg, 
0.037 mmol) in toluene (0.3 ml) Was added at room tem 
perature a solution of methyl (triphenylphosphoranylidene 
)acetate (93 mg, 0.277 mmol) in toluene (0.7 ml). The 
resulting mixture Was stirred at re?ux for 24 h and then 
concentrated under reduced pressure. The residue Was puri 
?ed by silica gel column chromatography (hexane-AcOEt, 
6:1) to give rac-(4R,5S,6S)-1—benzyloxy-6-tert-butyldim 
ethylsilyloxy-7-methylen-5-trimethylsilyloxy-1 -azaspiro 
[3.5]nona-8-en-2-on-10,8-carbolactone (10) as a yelloW oil 
(44 mg, 71%). 
[0105] Rf=0.55 (TLC, hexane-AcOEt, 3:1); yield, 26%; 
yelloW oil; 1H-NMR (200 MHz, CDCl3): 6 7.35-7.26 (5H, 
m, Ph), 5.91 (1H, m, H-9 or H-10), 4.99 (1H, partAsyst.AB, 
J=11.5 Hz, OCH2Ph), 4.99 (1H, d, J=1.8 Hz, H-10 or H-9), 
4.87 (1H, part B syst. AB, J=11.5 Hz, OCH2Ph), 4.73 (1H, 
d, J=2.6 Hz, H-5 or H-6), 3.97 (1H, d, J=2.6 Hz, H-6 or H-5), 
3.42 (1H, partA syst. AB, J=13.9 Hz, H-3), 2.47 (1H, part 
B syst. AB, J=13.9 Hz, H-3), 0.78 (9H, S, C(CH3)3), 0.20 
(3H, s, SiCH3), 0.12 (9H, s, Si(CH3)3), 0.07 (3H, s, SiCH3); 
LRMS(APl-ES+): m/z 538(M+Na)+, 516(M+H)+. 
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Example 9 
[0106] Preparation of rac-(4R,5S,6S,7R)-1-benZyloxy 
tert-butyldimethylsiyloxy-7 -hydroxy-7ethoxycarbonylm 
ethyl-5trimethylsilyloxy-1-aZaspiro[3.5]nona-8-en-2-ne 
(1 1) 
ClCOzEt, i-PrZEtN, DMAP 
CHZClZ, II 
[0107] To a solution of rac-(4R,5S,6S,7R)-1-benZyloxy 
&tert-butyldimethylsilyloxy-7-hydroxy-7-hydroxymethyl 
5-trimethylsilyloxy-1-aZaspiro[3.5]nona-8-en-2-one (4) (52 
mg, 0.102 mmol) and DMAP (1.3 mg, 0.010 mmol) in 
CHZCl2 (1.5 ml) Was added at 00 C. N-ethyldiisopropy 
lamine (42 ill, 0.245 mmol) and ethyl chloroformate (12 pl, 
0.122 mmol). The resulting mixture Was stirred at room 
temperature until the reaction Was complete (16 h, TLC 
monitoring, hexane-AcOEt, 1:1). The reaction Was 
quenched With H2O (drops), AcOEt (1.5 ml) and saturated 
NH4Cl/NH4OH solution (1.5 ml). The layers Were separated 
and aqueous phase Was extracted With AcOEt (3 x3 ml). The 
combined extracts Were Washed With saturated NH4Cl/ 
NH4OH solution (5 ml), dried over Na2SO4, ?ltered and 
concentrated under reduced pressure to give rac-(4R,5S,6S, 
7R)-1-benZyloxy-6-tert-butyldimethylsilyloxy-7-hydroxy 
7-ethoxycarbonylmethyl-5 -trimethylsilyloxy- 1 -aZaspiro 
[3.5]nona-8-en-2-one (11) as a loW melting point pale 
yelloW solid (50 mg, 85%). 
[0108] Rf=0.32 (TLC, hexane-AcOEt, 3:1), 0.73 (TLC, 
hexane-AcOEt, 1:1); yield, 85%; pale yelloW solid; 
1H-NMR (200 MHZ, CDCl3): 6 7.42-7.29 (5H, m, Ph), 5.48 
(1H, d, J=10.1 HZ, H-8 or H-9), 5.42 (1H, m, H-8 or H-9), 
4.98 (1H, part A syst. AB, J=11.3 HZ, OCHzPh), 4.85 (1H, 
partiByst. AB, J=11.3 HZ, OCHjPh), 4.55 (1H, br. s, H-5 or 
H-6 or H-10), 4.22 (1H, q, J=14.4, 7.1 HZ, OCH2CH3), 4.22 
(1H, q, J=14.2, 7.1 HZ, OCHCH3), 4.13 (1H, br. s, H-6 or 
Hl-10 orH-5), 3.88 (1H, br. s, H-10 or H-5 orH-6), 3.23 (1H, 
14 
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part A syst. AB, J=13.4 HZ, H-3), 2.27 (1H, br. s, H-10 or 
H-5 or H-6), 2.26 (1H, part B syst. AB, J=13.4 HZ, H-3), 
1.32 (3H, t, J=7.1 HZ, OCH2CHb), 0.80 (9H, s, C(CH3)3), 
0.18 (9H, s, Si(CH3)3), 0.15 (3H, s, SiCH3), 0.06 (3H, s, 
SiCH3); LRMS(APl-ES+): m/Z 1181(2M+Na)+, 602(M+ 
Na)", 580(M+H)+. 
Example 10 
[0109] Preparation of rac-(4R,5S,6S,7R)-1-benZyloxytert 
butyldimethylsilyloxy-7 -methyl-5-trimethylsilyloxy-7, 
10phenylboranediyldioxy- 1 -aZaspiro[3 .5 ]nonaen-2 -one 
(12) 
[0110] To a solution of N-methylmorpholine N-oxide (18 
mg, 0.149 mmol) and phenylboric acid (19 mg, 0.149 mmol) 
in CH2Cl2 (0.25 ml) Was added sequentially at room tem 
perature osmium tetroxide (32 pl, 0.5 mM solution in 
CH2Cl2, 0.0025 mmol) and a solution of rac-(4R,5S,6S)-1 
benZyloxystert-butyldimethylsilyloxy-7-methylen-5-trim 
ethylsilyloxy-1-aZaspiro[3.5]nona-8-en-2-one (3) (59 mg, 
0.124 mmol) in CH2Cl2 (0.5 ml). The resulting mixture Was 
stirred at room temperature until the reaction Was complete 
(2 h, TLC monitoring, hexane-AcOEt, 3:1), and then 
quenched With 10% aqueous Na2S2O3 solution (0.5 ml). 
After 15 min, the mixture Was extracted With AcOEt (3><2 
ml) and the combined organic extracts Were dried over 
Na2SO4, ?ltered and concentrated under reduced pressure. 
The residue Was puri?ed by silica gel column chromatog 
raphy (hexane-AcOEt, 5:1) to give rac-(4R,5S,6S,7R)-1 
benZyloxy-6-tert-butyldimethylsilyloxy-7-methyl-5-trim 
ethylsilyloxy-7,10-phenylboranediyldioxy-1-aZaspiro[3.5] 
nona-8-en-2-one (12) as a loW melting point White solid (33 
mg, 45%). 
[0111] Rf=0.40 (TLC, hexane-AcOEt, 3:1); yield, 45%; 
White solid; 1H-NMR (200 MHZ, CDCl3): 6 7.84 (2H, dd, 
J=8.1, 1.5 HZ, Ph), 7.56-7.30 (8H, m, Ph), 6.91, 5.52 (1H, 
m), 5.52 (1H, m), 5.07 (1H, part A syst. AB, J=10.1 HZ, 
OCHzPh), 4.93 (l H, part B syst. AB, J=10.1 HZ, OCHzPh), 
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4.71 (1H, br. s), 4.60-4.30 (1H, m), 4.10-3.80 (2H, m), 3.26, 
2.33 (1H, br. s), 2.59 (1H, br. s), 0.80 (9H, s, C(CH3)3), 0.17 
(9H, s, Si(CH3)3), 0.10 (3H, s, SiCH3), 0.07 (3H, s, SiCH3). 
Example 1 1 
[0112] Preparation of rac-(4R,5S,6S,7R)-1-benzyloxy6,7 
bis(tert-butyldimethylsilyloxy-7-hydroxy-5 -trimethylsily 
loxy-1-azaspiro[3.5]nona-8en-2-one (13) 
TBDMSCl, imidazole 
—>
DMF, 00 C. to r.t 
[0113] To a solution of rac-(4R,5S,6S,7R)-1-benzyloxy-6 
tert-butyldimethylsilyloxy-7-hydroxy-7-hydroxymethyl-5 
trimethylsilyloxy-1-azaspiro[3.5]nona-8en-2-one (4) (50 
mg, 0.098 mmol) and imidazole (8 mg, 0.118 mmol) in 
DMF (0.25 ml) Was added at 00 C. a solution of tert 
butyldimethylsilyl chloride (18 mg, 0.118 mmol) in DMF 
(0.25 ml). After 5 h at room temperature, the reaction Was 
quenched With H20 (1 ml) and the mixture extracted With 
AcOEt (3x2 ml). The combined extracts Were Washed With 
saturated aqueous CuSO4 solution (2x3 ml) and brine (2x3 
ml), dried over Na2SO4, ?ltered and concentrated under 
reduced pressure. The residue Was puri?ed by silica gel 
column chromatography (hexane-AcOEt, 6:1) to give rac 
(4R,5S,6S,7R)-1-benzyloxy-6,7-bis(tert-butyldimethylsily 
loxy)-7-hydroxy-5 -trimethylsilyloxy-1-azaspiro[3.5]nona 
8-en-2-one (13) as a White solid (50 mg, 82%). 
[0114] Rf=0.69 (TLC, hexane-AcOEt, 3:1); yield, 82%; 
White solid; 1H-NMR (200 MHZ, CDCl3): 67.44-727 (SH, 
m, Ph), 5.55 (2H, m, H-8 and H-9), 4.97 (1H, part A syst. 
AB, J=11.1 Hz, OCH2Ph), 4.88 (1H, part B syst.AB, J=11.1 
Hz, OCH2Ph), 4.62 (1H, br. s, H-5 or H-6), 3.81 (1H, br. s, 
H-6 or H-5), 3.62 (1H, part A syst. AB, J=9.6 Hz, OCH, 
CH3), 3.54 (I H, part B syst. AB, J=9.6 Hz, OCH2CH3), 3.23 
(1H, partA syst. AB, J=13.6 Hz, H-3), 2.94 (1H, br. s, OH), 
2.26 (1H, part B syst. AB, J=13.6 Hz, H-3), 1.32 (3H, t, 
J=7.1 Hz, OCH2CH3), 0.92 (9H, s, C(CH3)3), 0.81 (9H, s, 
C(CH3)3), 0.17 (9H, S, Si(CH3)3), 0.14 (3H, s, SiCH3), 0.09 
(6H, s, SiCH3), 0.06 (3H, s, SiCH3). 
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1. A compound of formula I: 
formula 1 
R5 R6 
R3 R2 
R4 R1 
Z N W 
Y \Y/ 
O 
wherein R1 and R2 are each independently selected from H, 
OH or OPR; 
R3 and R4 are each independently selected from H, OH, 
OPR, =O, cyano, substituted or unsubstituted alkyl, 
substituted or unsubstituted aryl, substituted or unsub 
stituted heterocyclyl, substituted or unsubstituted 
alkoxy, substituted or unsubstituted aryloxy, substituted 
or unsubstituted amino or halogen, 
R5 and R6 together are =O or 4Oi(CH2)mi, Wherein 
m is selected from 1, 2, 3, 4 or 5; or R5 is selected from 
H. OH, or OPR. and R6 is selected from hydrogen, 
cyano, substituted or unsubstituted alkyl, substituted or 
unsubstituted cycloalkyl, substituted or unsubstituted 
alkenyl, substituted or unsubstituted alkynyl, substi 
tuted or unsubstituted aryl, substituted or unsubstituted 
heterocyclyl, 
With the proviso that at least one of R1, R2, R3, R4 or R5 
is OH or OPR; PR is an hydroxyl protecting group 
Which can be the same or different on each of R1, R2, 
R3, R4 or R5; 
the dotted line represents a single or double bond, With the 
proviso that When both R1 and R2 or R3 and R4 are H 
then there is a double bond betWeen the tWo C to Which 
the H are linked; 
Z is 4CRaRb)ni Wherein n is a number selected from 1, 
2 or 3 and Ra and Rb are each independently selected 
from hydrogen, substituted or unsubstituted alkyl, sub 
stituted or unsubstituted cycloalkyl, substituted or 
unsubstituted alkenyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heterocyclyl, substituted or 
unsubstituted alkoxy, substituted or unsubstituted ary 
loxy, substituted or unsubstituted amino or halogen; 
Y is selected from iOi, iSi, iN(RaRb)i or 
4C(O)i, Wherein Ra and Rb are as previously 
de?ned and do not form a cyclic ring; 
W is a group selected from substituted or unsubstituted 
arylalkyl, substituted or unsubstituted heterocyclyla 
lkyl, substituted or unsubstituted alkenyl; 
or a salt, complex or solvate thereof. 
2. A compound according to claim 1 characterized in that 
Z is -(CHRa)ni , Ra and n being as de?ned in claim 1. 
3. A compound according to claim 1 characterized in that 
n is 1. 
4. A compound according to claim 1 characterized in that 
Y is iOi. 
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5. A compound as de?ned in claim 1 characterized in that 
W is iCRaRb-Q, wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
6. Acompound according to claim 1 Which corresponds to 
any of the following formulae: 
oPRl 
oPR2 
O 
oPRl 
Nu oPR2 
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-continued 
oPR3 
HQ 
" oPRl oPRl 
oPR2 Nu oPR2 
Z N Z N W 
Y \Y_W Y \Y 
o 0 
HO \Nu Pr3O \Nu 
“ oPRl Pr4O/,’I " OPrl 
Ho““ OPrZ 
Wherein Z, Y and W are as de?ned in claim 1; PRl to PR5 
are hydroxyl protecting groups Which can be independently 
the same or different on each hydroxyl and can optionally 
protect at the same time tWo hydroxyl groups, and Nu is a 
nucleophilic group; their diastereoisomers, enantiomers and 
mixtures thereof. 
7. A process for the preparation of a compound according 
to claim 1 Which comprises in any order one or more of a 
step selected from the group consisting of: 
a) hydroxylation or dihydroxylation 
b) hydroxyl or carbonyl protection 
c) nucleophilic attack on the carbonyl group 
d) hydroxyl inversion 
e) allylic rearrangement 
applied to a compound of formula IV: 
formula IV 
0 
Z N W 
Y \ Y / 
0 
wherein Z , Y and W are as de?ned in claim 1. 
US 2006/0148778 A1 
8. A compound according to claim 2 characterized in that 
n is 1. 
9. A compound according to claim 2 characterized in that 
Y is 40*. 
10. A compound according to claim 3 characterized in that 
Y is 40*. 
11. A compound according to claim 8 characterized in that 
Y is 40*. 
12. A compound as de?ned in claim 2 characterized in that 
W is iCRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
13. A compound as de?ned in claim 3 characterized in that 
W is iCRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
14. A compound as de?ned in claim 4 characterized in that 
W is iCRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
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15. Acompound as de?ned in claim 8 characterized in that 
W is iCRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
16. Acompound as de?ned in claim 9 characterized in that 
W is iCRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
17. A compound as de?ned in claim 10 characterized in 
that W is 4CRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
18. A compound as de?ned in claim 11 characterized in 
that W is CRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
